Latest round: IPO. David Kirn, M.D., is the Co-founder, CEO, and Director of 4D Molecular Therapeutics (4DMT).
David Kirn, M.D., is the Co-founder, CEO, and Director of 4D Molecular Therapeutics (4DMT), having led the company since its inception in 2013. He also serves as President of the company, a role he assumed in January 2026. Kirn leads a clinical-stage biopharma company specializing in novel, precision AAV vectors for gene therapies generated through a proprietary directed evolution platform.
Full founder directory · Investor directory · Company funding database · Fundraising library